English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
Australia520 mgTirzepatide 40 mg · Semaglutide 2 mg · Dihexa 10 mg
View all

Metabolic and incretin research

Retatrutide 20mg + Tirzepatide 40mg

Vendor-defined 1:2 retatrutide/tirzepatide analytical blend · no direct combination evidence

Per batch COACAS 2381089-83-2RUO
Research statusNo Direct Combination Evidence / Research Use Only
Supplied formTwo-component mixture of distinct 39-residue lipidated peptides
Lead timeConfirmed with quote
Retatrutide 20mg + Tirzepatide 40mg — Lyophilized material; confirm released-lot appearance on the COA
Retatrutide 20mg + Tirzepatide 40mg — Lyophilized material; confirm released-lot appearance on the COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • No health or weight-management benefit has been established for the blend
  • Separate trials show pharmacologic activity for each single agent, but both engage GIP and GLP-1 receptors and no evidence demonstrates that combining them improves outcomes versus either agent alone
  • The scientifically supportable uses of this material are limited to properly controlled analytical, formulation, stability or exploratory in vitro research.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
2381089-83-2
Formula
Not applicable — mixture or multi-component material
Molecular weight
Component-specific; no single molecular weight
Appearance
Lyophilized material; confirm released-lot appearance on the COA
Purity
Per batch COA
Storage
Store and ship according to the batch COA and validated stability data for this exact two-component formulation. Single-agent labels do not establish stability for a mixed lyophilizate or reconstituted blend. Require component-specific recovery, degradation and ratio-stability data across temperature, light, container, diluent and freeze-thaw conditions.
MOQ
On request
Lead time
Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Retatrutide 20mg + Tirzepatide 40mg

This catalogue item is a vendor-defined physical mixture labelled as 20 mg retatrutide plus 40 mg tirzepatide. It is not an Eli Lilly product, an FDA-approved fixed-dose combination or a formulation evaluated in a qualifying clinical or preclinical co-administration study identified in this review. Retatrutide is an investigational GIP/GLP-1/glucagon receptor agonist; tirzepatide is an approved GIP/GLP-1 receptor agonist only in specific regulated drug products. Evidence for either component alone cannot be used to claim additive efficacy, acceptable exposure or safety for this mixture. FDA currently states that retatrutide cannot be used in compounding under U.S. federal law and has not been found safe and effective for any condition.

  • No clinical indication applies to this mixture
  • Suitable research questions include component-specific LC-MS quantitation, blend homogeneity, ratio recovery, forced-degradation and compatibility studies, and carefully controlled in vitro receptor assays
  • Obesity, diabetes, liver-fat and cardiovascular results belong to the individual agents and are not indications for the blend.

Mechanism context

The question the literature is testing

Retatrutide and tirzepatide are distinct long-acting lipidated peptides. Retatrutide activates GIP, GLP-1 and glucagon receptors; tirzepatide activates GIP and GLP-1 receptors. A mixture therefore contains overlapping GIPR/GLP-1R agonism plus retatrutide's GCGR activity, but receptor occupancy, bias, desensitization, protein binding, exposure and tolerability for co-administration have not been established. Mechanistic overlap is not evidence of synergy.

Evidence map

Research routes and exposure context

Evidence tierAnalytical / laboratory context
Routes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • No combination-specific clinical safety, pharmacokinetic, toxicology, immunogenicity or dose-escalation data exist
  • Individual-agent adverse-event and warning information cannot quantify risk for the mixture
  • The FDA boxed warning and contraindications apply to approved tirzepatide products; retatrutide has no FDA-approved label, and FDA currently states that it cannot be used in compounding under U.S. federal law
  • This material is for laboratory research only and not for human or veterinary administration.

Interactions reported in the literature

  • The current FDA Zepbound label does not recommend tirzepatide coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist
  • Retatrutide is an investigational GLP-1/GIP/glucagon agonist, so this limitation is directly relevant to the proposed pairing
  • No validated compatibility, synergy, mitigation peptide or additional stacking protocol exists for the mixture.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Retatrutide 20mg + Tirzepatide 40mg factory batch COAs

Retatrutide 20mg + Tirzepatide 40mg 60 mg Factory batch COA protected previewRetatrutide 20mg + Tirzepatide 40mg60 mg · WHJLP-RETA60-260323-D
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • A visual check cannot verify a two-peptide blend
  • Require independent identity confirmation for both components by high-resolution intact mass and sequence-confirming MS/MS or peptide mapping; orthogonal chromatographic separation; component-specific net content showing the claimed 20:40 mg amount and 1:2 ratio; blend homogeneity and vial-to-vial uniformity; impurity and degradant profiles for each peptide; counterions, water, residual solvents, endotoxin or microbiological claims where applicable; and stability data demonstrating ratio retention
  • A single aggregate HPLC purity percentage is not sufficient.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
RTTR-60MG60 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Store and ship according to the batch COA and validated stability data for this exact two-component formulation. Single-agent labels do not establish stability for a mixed lyophilizate or reconstituted blend. Require component-specific recovery, degradation and ratio-stability data across temperature, light, container, diluent and freeze-thaw conditions.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • The 2023 NEJM retatrutide phase 2 trial, 2024 Nature Medicine liver-fat substudy and Lilly’s May 2026 TRIUMPH-1 release describe retatrutide alone. SURMOUNT-1, tirzepatide safety reviews and the current FDA Zepbound label describe tirzepatide alone. ClinicalTrials.gov NCT06662383 compares retatrutide with tirzepatide in separate arms; it does not co-administer them. FDA’s current unapproved-GLP-1 information states that retatrutide cannot be used in compounding under U.S. federal law. No qualifying source reviewed evaluates this 20 mg plus 40 mg mixture.
  1. 01

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

    New England Journal of Medicine · 2023 · peer-reviewed original research (randomized, double-blind, placebo-controlled phase 2 trial)

    Open source
  2. 02

    Triple Agonism Based Therapies for Obesity

    Current Cardiovascular Risk Reports · 2025 · peer-reviewed narrative review

    Open source
  3. 03

    Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

    Nature Medicine · 2024 · peer-reviewed original research (randomized, double-blind, placebo-controlled phase 2a substudy)

    Open source
  4. 04

    Tirzepatide Once Weekly for the Treatment of Obesity

    New England Journal of Medicine · 2022 · peer-reviewed original research (randomized, double-blind, placebo-controlled phase 3 trial)

    Open source
  5. 05

    A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?

    Frontiers in Endocrinology · 2023 · peer-reviewed systematic review

    Open source
  6. 06

    Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

    Eli Lilly and Company (Investor Relations) · 2026 · company press release / official investor communication

    Open source
  7. 07

    FDA Approves New Medication for Chronic Weight Management

    U.S. Food and Drug Administration · 2023 · regulatory document / official government press announcement

    Open source

Product FAQ

Questions buyers ask about Retatrutide 20mg + Tirzepatide 40mg

How should the claimed 20 mg retatrutide plus 40 mg tirzepatide composition be verified?+

Treat the vial as two analytes, not one 60 mg peptide. Require independent high-resolution intact mass and sequence-confirming identity for each component, orthogonal separation, component-specific net peptide content demonstrating 20 mg and 40 mg, the 1:2 ratio, blend homogeneity and vial-to-vial uniformity. Also report component-specific impurities and degradants, counterions, water and residual solvents. A single total fill mass or aggregate HPLC area-purity result cannot verify identity, ratio or net content.

What stability evidence is needed for a two-peptide blend?+

Require data for the exact finished formulation rather than two starting-material COAs. The protocol should measure recovery, ratio retention, adsorption, aggregation and component-specific degradation under intended shipping, temperature-excursion, light, moisture, container, diluent, concentration and freeze-thaw conditions. It should also explain whether the peptides were co-lyophilized or blended after separate manufacture and whether label amounts are net peptide or salt mass.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Metabolic and incretin research

Semaglutide

Lipidated GLP-1 analog · analytical and metabolic research reagent

Purity
Target ≥ 99.0% · Batch COA
CAS
910463-68-2
Latest batch COA available on request
Metabolic and incretin research

Liraglutide

GLP-1 receptor agonist · 31-mer metabolic reference standard

Purity
Target ≥ 99.0% · Batch COA
CAS
204656-20-2
Latest batch COA available on request
Metabolic and incretin research

Survodutide

GLP-1 / glucagon dual agonist · metabolic research peptide (BI 456906)

Purity
Target ≥ 99.0% · Batch COA
CAS
2805997-46-8
Latest batch COA available on request
Metabolic and incretin research

Cagrilintide

Long-acting lipidated amylin analogue research reference

Purity
Lot-specific · Batch COA
CAS
1415456-99-3
Latest batch COA available on request